Maša Alečković

Maša Alečković

Auto-generated profile, based on publicly available information

Maša Alečković

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 May 2012 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
Hector PeinadoHector Peinado
Hector Peinado
MAMaša Alečković
Maša Alečković
SLSimon Lavotshkin
Simon Lavotshkin
IMIrina Matei
Irina Matei
BCBruno Costa-Silva
Bruno Costa-Silva
DLDavid Lyden
David Lyden

1 November 2012 in Cancer Cell
Verified
Journal Article
Closed access
THTaro Hitosugi
Taro Hitosugi
LZLu Zhou
Lu Zhou
SEShannon Elf
Shannon Elf
JFJun Fan
Jun Fan
HKHee-Bum Kang
Hee-Bum Kang
JCJing Chen
Jing Chen

1 February 2014 in Molecular Cell
Verified
Journal Article
Closed access
JFJun Fan
Jun Fan
CSChangliang Shan
Changliang Shan
HKHee-Bum Kang
Hee-Bum Kang
SEShannon Elf
Shannon Elf
JXJianxin Xie
Jianxin Xie
JCJing Chen
Jing Chen

1 July 2019 in Nature Cell Biology
Verified
Journal Article
Open access
PDF file
MJMichalina Janiszewska
Michalina Janiszewska
DTDoris P. Tabassum
Doris P. Tabassum
ZCZafira Castaño
Zafira Castaño
SCSimona Cristea
Simona Cristea
KYKimiyo N. Yamamoto
Kimiyo N. Yamamoto
KPKornelia Polyak
Kornelia Polyak
Most human tumours are heterogeneous, composed of cellular clones with different properties present at variable frequencies. Highly heterogeneous tumours have poor clinical outcomes, yet the underlying mechanism remains poorly understood. Here, we show that minor subclones of breast cancer cells expressing IL11 and FIGF (VEGFD) cooperate to promote metastatic progression and generate polyclonal metastases composed of driver and neutral subclones. Expression profiling of the epithelial and stromal compartments of monoclonal and polyclonal primary and metastatic lesions revealed that this cooperation is indirect, mediated through the local and systemic microenvironments. We identified neutrophils as a leukocyte population stimulated by the IL11-expressing minor subclone and showed that the depletion of neutrophils prevents metastatic outgrowth. Single-cell RNA-seq of CD45+ cell populations from primary tumours, blood and lungs demonstrated that IL11 acts on bone-marrow-derived mesenchymal stromal cells, which induce pro-tumorigenic and pro-metastatic neutrophils. Our results indicate key roles for non-cell-autonomous drivers and minor subclones in metastasis.

1 June 2011 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
MBMario Andres Blanco
Mario Andres Blanco
MAMaša Alečković
Maša Alečković
YHYuling Hua
Yuling Hua
TLTuo Li
Tuo Li
YWYong Wei
Yong Wei
YKYibin Kang
Yibin Kang
Metastasis is the deadliest and most poorly understood feature of malignant diseases. Recent work has shown that Metadherin (MTDH) is overexpressed in over 40% of breast cancer patients and promotes metastasis and chemoresistance in experimental models of breast cancer progression. Here we applied mass spectrometry-based screen to identify staphylococcal nuclease domain-containing 1 (SND1) as a candidate MTDH-interacting protein. After confirming the interaction between SND1 and MTDH, we tested the role of SND1 in breast cancer and found that it strongly promotes lung metastasis. SND1 was further shown to promote resistance to apoptosis and to regulate the expression of genes associated with metastasis and chemoresistance. Analyses of breast cancer clinical microarray data indicated that high expression of SND1 in primary tumors is strongly associated with reduced metastasis-free survival in multiple large scale data sets. Thus, we have uncovered SND1 as a novel MTDH-interacting protein and shown that it is a functionally and clinically significant mediator of metastasis.

1 April 2020 in Cancer Immunology Research
Verified
Journal Article
Open access
PDF file
CACarlos R. Gil Del Alcazar
Carlos R. Gil Del Alcazar
MAMaša Alečković
Maša Alečković
KPKornelia Polyak
Kornelia Polyak
Immunotherapy using checkpoint inhibitors is one of the most promising current cancer treatment strategies. However, in breast cancer, its success has been limited to a subset of patients with triple-negative disease, whose durability of observed responses remain unclear. The lack of detailed understanding of breast tumor immune evasion mechanisms and the treatment of patients with highly heterogeneous metastatic disease contribute to these disappointing results. Here we discuss the current knowledge about immune-related changes during breast tumor progression, with special emphasis on the in situ-to-invasive breast carcinoma transition that may represent a key step of immunoediting in breast cancer. Comprehensive characterization of early-stage disease and better understanding of immunologic drivers of disease progression will likely expand the tools available for immunotherapy and improve patient stratification.